CDIM9 Inhibits Growth of Basal-Like Breast Cancer
Author Information
Author(s): Su Yunpeng, Vanderlaag Kathryn, Ireland Courtney, Ortiz Janelle, Grage Henry, Safe Stephen, Frankel Arthur E
Primary Institution: Scott & White Cancer Research Institute
Hypothesis
The study investigates the anti-basal-like breast tumor activity of CDIM9 in vitro and in vivo.
Conclusion
CDIM9 showed potent antiproliferative effects on basal-like breast cancer cells in tissue culture and significant growth inhibition in animal models at safe doses.
Supporting Evidence
- CDIM9 inhibited the growth of MDA-MB231 tumor xenografts by 87%.
- 46% of treated mice had complete durable remissions.
- CDIM9 treatment resulted in a mean tumor growth inhibition of 67%.
Takeaway
CDIM9 is a new drug that helps stop the growth of a type of breast cancer called basal-like breast cancer, and it worked well in mice.
Methodology
The study used in vitro cell lines and in vivo mouse models to assess the effects of CDIM9 on breast cancer growth.
Limitations
The study primarily focused on animal models, and the effects in humans are yet to be determined.
Participant Demographics
The study involved athymic nude mice, which are commonly used in cancer research.
Statistical Information
P-Value
0.009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website